334 related articles for article (PubMed ID: 29063804)
21. Long-term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12-year experience.
Qin RX; Lim JH; Ly J; Fischer J; Smith N; Karalus M; Wu L; van Dalen R; Lolohea S
ANZ J Surg; 2024 Apr; 94(4):621-627. PubMed ID: 37994292
[TBL] [Abstract][Full Text] [Related]
22. Single centre guidelines for radiological follow-up based on 775 patients treated by cytoreductive surgery and HIPEC for appendiceal pseudomyxoma peritonei.
Govaerts K; Chandrakumaran K; Carr NJ; Cecil TD; Dayal S; Mohamed F; Thrower A; Moran BJ
Eur J Surg Oncol; 2018 Sep; 44(9):1371-1377. PubMed ID: 30017331
[TBL] [Abstract][Full Text] [Related]
23. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review.
Floriano I; Silvinato A; Reis JC; Cafalli C; Bernardo WM
Clinics (Sao Paulo); 2022; 77():100039. PubMed ID: 35576869
[TBL] [Abstract][Full Text] [Related]
25. Clinical findings of patients with pseudomyxoma peritonei of appendiceal origin undergoing Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Iavazzo C; Spiliotis J
Updates Surg; 2020 Sep; 72(3):923-924. PubMed ID: 32602012
[No Abstract] [Full Text] [Related]
26. Impact of ovarian metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancy originating from appendiceal and colorectal cancer.
Bignell MB; Mehta AM; Alves S; Chandrakumaran K; Dayal SP; Mohamed F; Cecil TD; Moran BJ
Colorectal Dis; 2018 Aug; 20(8):704-710. PubMed ID: 29502336
[TBL] [Abstract][Full Text] [Related]
27. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
[TBL] [Abstract][Full Text] [Related]
28. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei].
Lei ZY; Ding BH; Wu QY; Luo JL; Li Z; Wang T; Wang YS; Chen YX; Huang LF; He JF; Yang XS; Guan TP; Ruan Q; Wang JH; Tang HS; Wang J; Cui SZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Dec; 26(12):1179-1186. PubMed ID: 38110280
[No Abstract] [Full Text] [Related]
30. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
[TBL] [Abstract][Full Text] [Related]
33. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.
Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S
J BUON; 2017; 22(1):251-257. PubMed ID: 28365962
[TBL] [Abstract][Full Text] [Related]
35. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
[TBL] [Abstract][Full Text] [Related]
36. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
37. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
38. Appendiceal pseudomyxoma peritonei: predictors of recurrence and iterative surgery.
Kong JC; Flood MP; Guerra GR; Liesegang A; Wong WJ; Mitchell C; Warrier SK; Naidu S; Meade B; Lutton N; Heriot AG
Colorectal Dis; 2021 Sep; 23(9):2368-2375. PubMed ID: 34157209
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of neoadjuvant chemotherapy before CRS-HIPEC for patients with appendiceal cancer.
Chen JC; Beal EW; Hays J; Pawlik TM; Abdel-Misih S; Cloyd JM
J Surg Oncol; 2020 Sep; 122(3):388-398. PubMed ID: 32383206
[TBL] [Abstract][Full Text] [Related]
40. Volume-Time Index Is Not an Indicator of Outcome for Patients Undergoing CRS/HIPEC for Treatment of High-Grade Appendiceal Carcinomatosis.
Dotta DM; Lansom JD; Fisher OM; Fracs NAA; Liauw W; Morris DL
Anticancer Res; 2019 Dec; 39(12):6813-6817. PubMed ID: 31810947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
